Indivior 
Welcome,         Profile    Billing    Logout  
 4 Products   23 Diseases  4 Products   7 Trials   315 News 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INDV-2000 / Indivior
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
NCT05694533: Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults

Completed
1
20
US
INDV-2000, C4X_3256, Midazolam
Indivior Inc., National Institute on Drug Abuse (NIDA)
Healthy
04/23
05/23
NCT04976855: Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

Completed
1
64
US
INDV-2000, C4X_3256, Placebo, SUBOXONE® sublingual film, Buprenorphine and naloxone
Indivior Inc., National Institute on Drug Abuse (NIDA)
Healthy Volunteer, Opioid-use Disorder
07/23
07/23
Sublocade (buprenorphine once-monthly depot) / Indivior
NCT05704543: Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

Completed
4
132
US
Buprenorphine Extended-Release Injection, SUBLOCADE®
Indivior Inc.
Opioid Use Disorder
11/23
11/23
STOPIT, NCT05594121: Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder

Not yet recruiting
4
90
Canada
Extended Release Subcutaneous Buprenorphine, Sublocade, Immediate Release Sublingual Buprenorphine, Suboxone
Royal Victoria Hospital, Canada
Moderate to Severe Opioid Use Disorder
12/23
12/24
INDV-6000-401, NCT04995029: Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

Completed
4
785
Canada, US
Transmucosal Buprenorphine, Extended-release Buprenorphine, RBP-6000, SUBLOCADE
Indivior Inc.
Moderate to Severe Opioid-use Disorder
06/24
06/24
NCT04219540: Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults

Completed
4
675
US
XR-B (SUBLOCADETM), SUBLOCADE TM, XR-NTX, Vivitrol®
NYU Langone Health, National Institute on Drug Abuse (NIDA)
Opioid-use Disorder
08/24
02/25
NCT06880718: Injectable Buprenorphine in Prison: a Preference Trial

Not yet recruiting
4
60
NA
Brixadi (Injectable Buprenorphine), CAM2308, Buvidal, Sublocade
Lifespan, National Institute on Drug Abuse (NIDA)
Opioid Use Disorder, Incarceration, Medications for Opioid Use Disorder, Buprenorphine
12/26
06/27
NCT06051890: Assessing Optimal XRB Initiation Points in Jail

Not yet recruiting
4
200
US
Extended-Release Buprenorphine (XRB), Sublocade, Sublingual Buprenorphine (SLB)
NYU Langone Health, National Institute on Drug Abuse (NIDA)
Opioid Use Disorder
12/26
03/27
NCT05481112: Assessing Optimal XR-Buprenorphine Initiation Points in Jail

Withdrawn
4
200
US
Extended-Release Buprenorphine Injection, Sublocade
NYU Langone Health, National Institute on Drug Abuse (NIDA)
Opioid Use Disorder
11/25
02/26
2018-004460-63: Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO)

Not yet recruiting
3
600
Europe
Sublocade, Buprenorphine, METHADONE, Buprenorphine-Naloxone, Espranor Oral lyophilisate, RBP-6000, Solution for infusion in pre-filled syringe, Sublingual tablet, Oral liquid, Oral lyophilisate, SUBOXONE, Espranor
South London and Maudsley NHS Foundation Trust, King's College London, INDIVIOR UK
Opiod addiction, Opiod Addiction, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
EXPO, NCT05164549: Extended-release Pharmacotherapy for Opioid Use Disorder

Completed
3
342
Europe
Buprenorphine Injectable Product, Sublocade®; prev. RBP-60000, Methadone, Buprenorphine, Suboxone, Espranor, Subutex
King's College London, South London and Maudsley NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust, Cumbria, Northumberland Tyne and Wear NHS Foundation Trust, Birmingham and Solihull Mental Health NHS Foundation Trust, NHS Tayside, Bangor University
Opiate Substitution Treatment
04/22
03/23
NCT04352166: Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder

Suspended
2
40
US
extended-release buprenorphine (BXR), Sublocade, sublingual buprenorphine (BSL), buprenorphine
Frances R Levin, National Institute on Drug Abuse (NIDA)
Opioid-use Disorder
06/25
06/25
BOPAT, NCT04677114: Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections

Completed
2
71
US
Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Suboxone or Sublocade, Buprenorphine and standard of care antibiotic treatment
Laura Fanucchi, National Institute on Drug Abuse (NIDA)
Drug Use, Opioid-use Disorder
03/25
03/25
NCT06576843: INDV-6001 Multiple-Dose Pharmacokinetic Study

Recruiting
2
122
US
INDV-6001, Suboxone, Sublocade
Indivior Inc.
Moderate to Severe Opioid Use Disorder
12/25
12/25
MURB, NCT05283304: Monthly Injectable BUP for MA Use Disorder () Trial

Terminated
2
18
US
Buprenorphine injection (BUP-Inj), SublocadeTM, Indivior, Placebo injection, Placebo injection (PBO-Inj)
Madhukar H. Trivedi, MD
Methamphetamine-dependence
10/23
11/23
CHOICE, NCT05991622: Combined Injectable Treatment for HIV and OUD

Recruiting
1
40
US
Combined LAI Treatment: Cabenuva and Sublocade, rilpivirine (CAB/RPV) "cabenuva", extended-release buprenorphine (XR-B) "sublocade"
Rhode Island Hospital
Human Immunodeficiency Virus, Opioid Use Disorder
04/24
10/24
NCT05878210: Evaluating the SUBLOCADE Treatment Exit Strategy

Completed
N/A
12
Canada, US
Indivior Inc.
Opioid Use Disorder
05/25
05/25
NCT05860959: SUBLOCADE Long-term Outcomes

Active, not recruiting
N/A
1200
Europe, Canada, US, RoW
Indivior Inc.
Opioid Use Disorder
08/25
08/25
AEF0117 / Indivior
SICA 2, NCT05322941: Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

Completed
2
333
US
AEF0117, 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one, Placebo oral capsule, Placebo
Aelis Farma, National Institute on Drug Abuse (NIDA)
Marijuana Abuse
04/24
07/24
NCT05554926: Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects

Completed
1
8
US
AEF0117, 3ß-(4-methoxybenzykoxy)pregn-5-en-20-one t)
Aelis Farma
Marijuana Abuse
02/23
02/23
NCT05451017: The Effect of Food on the Oral Bioavailability of AEF0117 in Healthy Volunteers

Terminated
1
24
US
3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition, AEF0117, 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition
Aelis Farma, National Institute on Drug Abuse (NIDA)
Marijuana Abuse
06/23
06/23
DDI, NCT06395688: Drug-Drug Interaction Between THC and AEF0117

Not yet recruiting
1
24
NA
3ß-(4-methoxybenzyloxy)pregn-5-en-20-one, AEF0117, Placebo
Aelis Farma, National Institute on Drug Abuse (NIDA)
Cannabis Abuse
06/25
06/25
drinabant (OPNT004) / Sanofi, Indivior
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INDV-2000 / Indivior
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
NCT05694533: Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults

Completed
1
20
US
INDV-2000, C4X_3256, Midazolam
Indivior Inc., National Institute on Drug Abuse (NIDA)
Healthy
04/23
05/23
NCT04976855: Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

Completed
1
64
US
INDV-2000, C4X_3256, Placebo, SUBOXONE® sublingual film, Buprenorphine and naloxone
Indivior Inc., National Institute on Drug Abuse (NIDA)
Healthy Volunteer, Opioid-use Disorder
07/23
07/23
Sublocade (buprenorphine once-monthly depot) / Indivior
NCT05704543: Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

Completed
4
132
US
Buprenorphine Extended-Release Injection, SUBLOCADE®
Indivior Inc.
Opioid Use Disorder
11/23
11/23
STOPIT, NCT05594121: Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder

Not yet recruiting
4
90
Canada
Extended Release Subcutaneous Buprenorphine, Sublocade, Immediate Release Sublingual Buprenorphine, Suboxone
Royal Victoria Hospital, Canada
Moderate to Severe Opioid Use Disorder
12/23
12/24
INDV-6000-401, NCT04995029: Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

Completed
4
785
Canada, US
Transmucosal Buprenorphine, Extended-release Buprenorphine, RBP-6000, SUBLOCADE
Indivior Inc.
Moderate to Severe Opioid-use Disorder
06/24
06/24
NCT04219540: Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults

Completed
4
675
US
XR-B (SUBLOCADETM), SUBLOCADE TM, XR-NTX, Vivitrol®
NYU Langone Health, National Institute on Drug Abuse (NIDA)
Opioid-use Disorder
08/24
02/25
NCT06880718: Injectable Buprenorphine in Prison: a Preference Trial

Not yet recruiting
4
60
NA
Brixadi (Injectable Buprenorphine), CAM2308, Buvidal, Sublocade
Lifespan, National Institute on Drug Abuse (NIDA)
Opioid Use Disorder, Incarceration, Medications for Opioid Use Disorder, Buprenorphine
12/26
06/27
NCT06051890: Assessing Optimal XRB Initiation Points in Jail

Not yet recruiting
4
200
US
Extended-Release Buprenorphine (XRB), Sublocade, Sublingual Buprenorphine (SLB)
NYU Langone Health, National Institute on Drug Abuse (NIDA)
Opioid Use Disorder
12/26
03/27
NCT05481112: Assessing Optimal XR-Buprenorphine Initiation Points in Jail

Withdrawn
4
200
US
Extended-Release Buprenorphine Injection, Sublocade
NYU Langone Health, National Institute on Drug Abuse (NIDA)
Opioid Use Disorder
11/25
02/26
2018-004460-63: Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO)

Not yet recruiting
3
600
Europe
Sublocade, Buprenorphine, METHADONE, Buprenorphine-Naloxone, Espranor Oral lyophilisate, RBP-6000, Solution for infusion in pre-filled syringe, Sublingual tablet, Oral liquid, Oral lyophilisate, SUBOXONE, Espranor
South London and Maudsley NHS Foundation Trust, King's College London, INDIVIOR UK
Opiod addiction, Opiod Addiction, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
EXPO, NCT05164549: Extended-release Pharmacotherapy for Opioid Use Disorder

Completed
3
342
Europe
Buprenorphine Injectable Product, Sublocade®; prev. RBP-60000, Methadone, Buprenorphine, Suboxone, Espranor, Subutex
King's College London, South London and Maudsley NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust, Cumbria, Northumberland Tyne and Wear NHS Foundation Trust, Birmingham and Solihull Mental Health NHS Foundation Trust, NHS Tayside, Bangor University
Opiate Substitution Treatment
04/22
03/23
NCT04352166: Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder

Suspended
2
40
US
extended-release buprenorphine (BXR), Sublocade, sublingual buprenorphine (BSL), buprenorphine
Frances R Levin, National Institute on Drug Abuse (NIDA)
Opioid-use Disorder
06/25
06/25
BOPAT, NCT04677114: Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections

Completed
2
71
US
Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Suboxone or Sublocade, Buprenorphine and standard of care antibiotic treatment
Laura Fanucchi, National Institute on Drug Abuse (NIDA)
Drug Use, Opioid-use Disorder
03/25
03/25
NCT06576843: INDV-6001 Multiple-Dose Pharmacokinetic Study

Recruiting
2
122
US
INDV-6001, Suboxone, Sublocade
Indivior Inc.
Moderate to Severe Opioid Use Disorder
12/25
12/25
MURB, NCT05283304: Monthly Injectable BUP for MA Use Disorder () Trial

Terminated
2
18
US
Buprenorphine injection (BUP-Inj), SublocadeTM, Indivior, Placebo injection, Placebo injection (PBO-Inj)
Madhukar H. Trivedi, MD
Methamphetamine-dependence
10/23
11/23
CHOICE, NCT05991622: Combined Injectable Treatment for HIV and OUD

Recruiting
1
40
US
Combined LAI Treatment: Cabenuva and Sublocade, rilpivirine (CAB/RPV) "cabenuva", extended-release buprenorphine (XR-B) "sublocade"
Rhode Island Hospital
Human Immunodeficiency Virus, Opioid Use Disorder
04/24
10/24
NCT05878210: Evaluating the SUBLOCADE Treatment Exit Strategy

Completed
N/A
12
Canada, US
Indivior Inc.
Opioid Use Disorder
05/25
05/25
NCT05860959: SUBLOCADE Long-term Outcomes

Active, not recruiting
N/A
1200
Europe, Canada, US, RoW
Indivior Inc.
Opioid Use Disorder
08/25
08/25
AEF0117 / Indivior
SICA 2, NCT05322941: Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

Completed
2
333
US
AEF0117, 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one, Placebo oral capsule, Placebo
Aelis Farma, National Institute on Drug Abuse (NIDA)
Marijuana Abuse
04/24
07/24
NCT05554926: Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects

Completed
1
8
US
AEF0117, 3ß-(4-methoxybenzykoxy)pregn-5-en-20-one t)
Aelis Farma
Marijuana Abuse
02/23
02/23
NCT05451017: The Effect of Food on the Oral Bioavailability of AEF0117 in Healthy Volunteers

Terminated
1
24
US
3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition, AEF0117, 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition
Aelis Farma, National Institute on Drug Abuse (NIDA)
Marijuana Abuse
06/23
06/23
DDI, NCT06395688: Drug-Drug Interaction Between THC and AEF0117

Not yet recruiting
1
24
NA
3ß-(4-methoxybenzyloxy)pregn-5-en-20-one, AEF0117, Placebo
Aelis Farma, National Institute on Drug Abuse (NIDA)
Cannabis Abuse
06/25
06/25
drinabant (OPNT004) / Sanofi, Indivior
No trials found

Download Options